PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study

PhaseBio Pharmaceuticals Inc PHAS has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old.
The trial in 150 subjects receiving bentracimab and 50 subjects receiving placebo after all were pretreated with dual antiplatelet therapy composed of AstraZeneca Plc's AZN Brilinta (ticagrelor) and low-dose aspirin.
Bentracimab is a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
The Phase 2b trial achieved its primary endpoint of reversing ticagrelor's inhibition of platelet function in actively treated subjects versus placebo.
Bentracimab is currently being evaluated in the REVERSE-IT Phase 3 trial in approximately 200 participants.
A prespecified interim analysis from the REVERSE-IT trial will be presented on November 15 at the American Heart Association's Scientific Sessions 2021.
PhaseBio is targeting marketing application submission to the FDA in mid-2022.
Also Read: CytoSorbents To Start US Study With CytoSorb For Ticagrelor Removal.
Price Action: PHAS shares are down 3.21% at $3.92 during the market session on the last check Wednesday.

Momentum61.44

Growth43.85

Quality57.37

Value18.57

Short

Medium

Long